These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 33494392)

  • 1. A Regulatory Loop of FBXW7-MYC-PLK1 Controls Tumorigenesis of MYC-Driven Medulloblastoma.
    Wang D; Pierce A; Veo B; Fosmire S; Danis E; Donson A; Venkataraman S; Vibhakar R
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33494392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel PLK1 inhibitor onvansertib effectively sensitizes MYC-driven medulloblastoma to radiotherapy.
    Wang D; Veo B; Pierce A; Fosmire S; Madhavan K; Balakrishnan I; Donson A; Alimova I; Sullivan KD; Joshi M; Erlander M; Ridinger M; Foreman NK; Venkataraman S; Vibhakar R
    Neuro Oncol; 2022 Mar; 24(3):414-426. PubMed ID: 34477871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma.
    Mai J; Zhong ZY; Guo GF; Chen XX; Xiang YQ; Li X; Zhang HL; Chen YH; Xu XL; Wu RY; Yu Y; Li ZL; Peng XD; Huang Y; Zhou LH; Feng GK; Guo X; Deng R; Zhu XF
    Theranostics; 2019; 9(12):3541-3554. PubMed ID: 31281496
    [No Abstract]   [Full Text] [Related]  

  • 5. Polo-Like Kinase 1 Pharmacological Inhibition as Monotherapy or in Combination: Comparative Effects of Polo-Like Kinase 1 Inhibition in Medulloblastoma Cells.
    Pezuk JA; Brassesco MS; Ramos PMM; Scrideli CA; Tone LG
    Anticancer Agents Med Chem; 2017; 17(9):1278-1291. PubMed ID: 28270075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer.
    Gasca J; Flores ML; Giráldez S; Ruiz-Borrego M; Tortolero M; Romero F; Japón MA; Sáez C
    Oncotarget; 2016 Aug; 7(33):52751-52765. PubMed ID: 27409838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Class I HDAC inhibitor entinostat synergizes with PLK1 inhibitors in MYC-amplified medulloblastoma cells.
    Valinciute G; Ecker J; Selt F; Hielscher T; Sigaud R; Ridinger J; Thatikonda V; Gatzweiler C; Robinson S; Talbot J; Bernardi F; Picard D; Blattner-Johnson M; Schmid S; Jones DT; van Tilburg CM; Capper D; Kool M; Remke M; Oehme I; Pfister SM; Roussel MF; Ayrault O; Witt O; Milde T
    J Neurooncol; 2023 May; 163(1):143-158. PubMed ID: 37183219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase 1 as a molecular target in high-risk children.
    Triscott J; Lee C; Foster C; Manoranjan B; Pambid MR; Berns R; Fotovati A; Venugopal C; O'Halloran K; Narendran A; Hawkins C; Ramaswamy V; Bouffet E; Taylor MD; Singhal A; Hukin J; Rassekh R; Yip S; Northcott P; Singh SK; Dunham C; Dunn SE
    Cancer Res; 2013 Nov; 73(22):6734-44. PubMed ID: 24019381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
    Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
    Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
    Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
    J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
    Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
    Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NSD3S stabilizes MYC through hindering its interaction with FBXW7.
    Gonzalez-Pecchi V; Kwan AK; Doyle S; Ivanov AA; Du Y; Fu H
    J Mol Cell Biol; 2020 Jul; 12(6):438-447. PubMed ID: 31638140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch.
    Ishikawa Y; Hosogane M; Okuyama R; Aoyama S; Onoyama I; Nakayama KI; Nakayama K
    Oncogene; 2013 Apr; 32(15):1921-32. PubMed ID: 22665065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of MYC-miR-29-B7-H3 in Medulloblastoma Growth and Angiogenesis.
    Purvis IJ; Avilala J; Guda MR; Venkataraman S; Vibhakar R; Tsung AJ; Velpula KK; Asuthkar S
    J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31382461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Fbxw7 expression and its correlation with the expression of c-Myc, cyclin E and p53 in human hepatocellular carcinoma.
    Tu K; Zheng X; Zan X; Han S; Yao Y; Liu Q
    Hepatol Res; 2012 Sep; 42(9):904-10. PubMed ID: 22548670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
    von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
    BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.
    Bolin S; Borgenvik A; Persson CU; Sundström A; Qi J; Bradner JE; Weiss WA; Cho YJ; Weishaupt H; Swartling FJ
    Oncogene; 2018 May; 37(21):2850-2862. PubMed ID: 29511348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional Regulation of Protein Synthesis by Mediator Kinase in MYC-driven Medulloblastoma.
    Wang D; Ritz C; Pierce A; Brunt B; Luo Y; Dahl N; Venkataraman S; Danis E; Kuś K; Mazan M; Rzymski T; Veo B; Vibhakar R
    bioRxiv; 2024 Mar; ():. PubMed ID: 38559100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas.
    Ren Y; Bi C; Zhao X; Lwin T; Wang C; Yuan J; Silva AS; Shah BD; Fang B; Li T; Koomen JM; Jiang H; Chavez JC; Pham LV; Sudalagunta PR; Wan L; Wang X; Dalton WS; Moscinski LC; Shain KH; Vose J; Cleveland JL; Sotomayor EM; Fu K; Tao J
    J Clin Invest; 2018 Dec; 128(12):5517-5530. PubMed ID: 30260324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.
    Fiore D; Piscopo C; Proto MC; Vasaturo M; Dal Piaz F; Fusco BM; Pagano C; Laezza C; Bifulco M; Gazzerro P
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.